All In Biotech

Investigational drug · Phase 2

Normal Saline along

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hypoxic-Ischemic Encephalopathy, Neonatal Asphyxia, Neonatal Encephalopathy.

Phase 2

Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

207

Any phase or sponsor naming "Normal Saline along"

First trial start

2019

Jan 10, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Normal Saline along", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hypoxic-Ischemic Encephalopathy
  • Neonatal Asphyxia
  • Neonatal Encephalopathy
  • Acute Spinal Cord Injury

Largest trials

Live from ClinicalTrials.gov: studies naming "Normal Saline along" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Hypoxic-Ischemic Encephalopathy

  • RLS-0071Phase 33 trials

    ReAlta Life Sciences, Inc. · Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Hypoxic-Ischemic Encephalopathy, Steroid Refractory GVHD

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.